Annexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage Study
Portfolio Pulse from Vandana Singh
Annexon Inc announced mixed topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA). The drug was not statistically significant compared to pooled sham at 12 months, but showed a reduction in the risk of 15-letter loss. ANX007 was well-tolerated, and the company plans to focus on a late-stage study.
May 25, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Annexon's ANX007 reports mixed results in Phase 2 trial for geographic atrophy patients, with plans to focus on a late-stage study.
The mixed results from the Phase 2 trial of ANX007 may cause short-term negative sentiment among investors, as the drug did not show statistical significance compared to pooled sham at 12 months. However, the reduction in the risk of 15-letter loss and the drug's well-tolerated nature may provide some optimism for the late-stage study. The stock price has already dropped 23.60% in premarket trading, indicating a negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100